Benzinga | Jun 3, 2021 08:27AM EDT

Updated Analysis Show Seagen's Tukysa Extended Median OS to Two Years with Benefits Maintained in Breast Cancer

* Seagen Inc (NASDAQ:SGEN) has announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow-up from the HER2CLIMB trial of Tukysa (tucatinib) in metastatic breast cancer (MBC).

* The trial evaluated the addition of Tukysa to trastuzumab and capecitabine in patients with HER2-positive MBC with and without brain metastases.

* Data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting.

* The overall survival benefit seen with Tukysa at the primary analysis time was maintained after an additional 15.6 months of follow-up, demonstrating a 5.5-month improvement in median OS to 24.7 months for the Tukysa regimen vs. 19.2 months for capecitabine and trastuzumab alone.

* The median progression-free survival in the Tukysa arm was 7.6 months, compared to the median PFS of 4.9 months in the control arm.

* The safety profile was generally consistent with the primary analysis.

* Related content: Benzinga's Full FDA Calendar.

* Price Action: SGEN shares closed at $148.16 on Wednesday.